Lupin Limited has reached a settlement and licensing agreement with Astellas Pharma and its group companies, bringing an end to the long-running patent infringement litigation related to the overactive bladder drug Mirabegron (marketed by Astellas as Myrbetriq).
Lupin said the agreement was signed by the company and its wholly owned US subsidiary, Lupin Pharmaceuticals, Inc., with Astellas Pharma, Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc.
Under the terms of the settlement, Lupin will pay Astellas a total of USD 90 million. This includes a prepaid option payment of USD 75 million, along with a prepaid per-unit licence fee for each unit of Lupin’s Mirabegron product sold from the settlement date through September 2027. The detailed commercial terms of the agreement remain confidential.
The settlement resolves all pending litigation between the parties and allows Lupin to continue marketing and selling its Mirabegron product in the agreed markets.
Lupin had earlier informed stock exchanges on April 16, 2025, about the patent infringement dispute with Astellas. The latest development marks a significant closure to the matter and provides business certainty for Lupin’s Mirabegron franchise going forward.
